SEC Comment Letter for VOLITIONRX LTD (VNRX) (CIK 0000093314) (VNRX) — Feb 13, 2020
VOLITIONRX LTD (VNRX) (CIK 0000093314)
Date: Feb. 13, 2020 · CIK: 0000093314 · Accession: 0000000000-20-001370
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-236335
Letter
February 13, 2020 Cameron Reynolds Chief Executive Officer VolitionRx Ltd. 13215 Bee Cave Parkway Suite 125, Galleria Oaks B Austin, TX 78738 Re:VolitionRx Ltd. Registration Statement on Form S-3 Filed February 7, 2020 File No. 333-236335 Dear Mr. Reynolds: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact William Mastrianna, Attorney-Adviser, at (202) 551-3778 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Marc Alcser
Show Raw Text
February 13, 2020
Cameron Reynolds
Chief Executive Officer
VolitionRx Ltd.
13215 Bee Cave Parkway
Suite 125, Galleria Oaks B
Austin, TX 78738
Re:VolitionRx Ltd.
Registration Statement on Form S-3
Filed February 7, 2020
File No. 333-236335
Dear Mr. Reynolds:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact William Mastrianna, Attorney-Adviser, at (202) 551-3778 with any
questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Marc Alcser